When Can a Pulmonary Embolism and Deep Vein Thrombosis Patient Fly Safely Again on Airplane? A Case Report

There was no recommendation in the current guidelines for how long after the pulmonary embolism (PE) attack the patient can fly again safely on an airplane. A 45 years old female was admitted to our hospital because of deep vein thrombosis and acute PE. Due to persistent leg swelling and afraid of recurrent PE for long distance flights, this patient received four weeks anticoagulant therapy before flying. Eventually, she flew back safely. This report describes our preliminary experience for managing this patient with deep vein thrombosis and PE.

Download Full-text

Deep Vein Thrombosis /Pulmonary Embolism in a Patient with Retroperitoneal Fibrosis: A Case Report

Journal of Clinical Case Reports ◽

10.4172/2165-7920.1000154 ◽

2012 ◽

Vol 02 (10) ◽

Cited By ~ 1

Author(s):

Harsh Agrawal

Keyword(s):

Pulmonary Embolism ◽

Deep Vein Thrombosis ◽

Case Report ◽

Retroperitoneal Fibrosis ◽

Vein Thrombosis ◽

Deep Vein

Download Full-text

Deep vein thrombosis and pulmonary embolism secondary to urinary retention: a case report

Journal of Medical Case Reports ◽

10.1186/s13256-018-1605-3 ◽

2018 ◽

Vol 12 (1) ◽

Cited By ~ 2

Author(s):

Tatsushi Kawada ◽

Takashi Yoshioka ◽

Motoo Araki ◽

Hiroyuki Nose ◽

Tadashi Oeda

Keyword(s):

Pulmonary Embolism ◽

Deep Vein Thrombosis ◽

Case Report ◽

Urinary Retention ◽

Vein Thrombosis ◽

Deep Vein

Download Full-text

Comparison of 3 and 6 Months of Oral Anticoagulant Therapy After a First Episode of Proximal Deep Vein Thrombosis or Pulmonary Embolism and Comparison of 6 and 12 Weeks of Therapy After Isolated Calf Deep Vein Thrombosis

Circulation ◽

10.1161/01.cir.103.20.2453 ◽

2001 ◽

Vol 103 (20) ◽

pp. 2453-2460 ◽

Cited By ~ 255

Author(s):

Laurent Pinede ◽

Jacques Ninet ◽

Pierre Duhaut ◽

Sylvie Chabaud ◽

Sylvie Demolombe-Rague ◽

...

Keyword(s):

Pulmonary Embolism ◽

Deep Vein Thrombosis ◽

Anticoagulant Therapy ◽

Oral Anticoagulant ◽

Oral Anticoagulant Therapy ◽

Proximal Deep Vein Thrombosis ◽

First Episode ◽

Vein Thrombosis ◽

Deep Vein

Download Full-text

Idiopathic Upper Extremity Deep Vein Thrombosis with Fatal Pulmonary Embolism: A Case Report

Open Access Journal of Cardiology ◽

10.23880/oajc-16000128 ◽

2018 ◽

Vol 2 (4) ◽

Author(s):

Priti K

Keyword(s):

Pulmonary Embolism ◽

Deep Vein Thrombosis ◽

Case Report ◽

Upper Extremity ◽

Fatal Pulmonary Embolism ◽

Vein Thrombosis ◽

Deep Vein

Download Full-text

Saddle pulmonary embolism with fluorouracil: A case report

Journal of Oncology Pharmacy Practice ◽

10.1177/1078155220909424 ◽

2020 ◽

Vol 26 (7) ◽

pp. 1769-1773

Author(s):

Kylee E White ◽

Christopher T Elder

Keyword(s):

Pulmonary Embolism ◽

Deep Vein Thrombosis ◽

Case Report ◽

Single Agent ◽

Vein Thrombosis ◽

Increased Risk ◽

Additive Risk ◽

The Right ◽

Deep Vein ◽

To Receive

Introduction As a single agent, fluorouracil has been documented to have a small but present chance of causing extravasation of the port when not properly administered. It has also been shown that cancer patients receiving chemotherapy are at increased risk of deep vein thrombosis, symptomatic or silent. Case report A 43-year-old male patient with stage III colon cancer receiving FOLFOX developed a saddle pulmonary embolism involving possible extravasation that was discovered following cycle 3 of chemotherapy. CT scan and lower extremity Doppler confirmed non-occlusive deep vein thrombosis along with saddle pulmonary embolism. Management and outcome: For acute management, patient underwent bilateral pulmonary artery thrombolysis. Following this, the patient was initiated on rivaroxaban indefinitely. The right subclavian port was removed, and a new port was placed in the left subclavian. Patient went on to receive three more cycles of chemotherapy. Discussion Fluorouracil, an inflammitant, has been shown to have damaging potential, especially in terms of the integrity of the endothelium. Over time, this can lead to serious complications such as cardiotoxicity, including deep vein thrombosis formation. Based on how and when the thrombi were discovered, it is not possible to deduce whether the port, the 5-FU, extravasation or other factors were the precipitators of the formation of the thrombi. The combination of chemotherapy treatment along with CVC placement appears to have an additive risk to the formation of a thrombus. Practitioners should take caution when evaluating for extravasation and CVC integrity and note other potential differentials for causes, including deep vein thrombosis/saddle pulmonary embolism formation.

Download Full-text